Home / Companies / News / Natco Pharma Q4 PBT down 23% at Rs 117 cr on decline in Hep C portfolio

Natco Pharma Q4 PBT down 23% at Rs 117 cr on decline in Hep C portfolio

Total income for the quarter down marginally to Rs 477.2 cr; full-year pre-tax at Rs 569 cr

Pharma, medicine, drugs, Pharmaceuticals

Premium

The overall decline in revenue and profits from the prior year was primarily due to continued decline in Hepatitis C product portfolio and to an extent in oncology segment due to pricing pressures

BS Reporter Hyderabad

2 min read Last Updated : Jun 17 2020 | 6:00 PM IST

Hyderabad-based Natco Pharma Limited has reported a 23.43 per cent decline in consolidated profit before tax (PBT) at Rs 116.7 crore for the quarter ended March 31, 2020 as compared to Rs 152.4 crore in the corresponding quarter previous year. Total income for the quarter under review declined marginally to Rs 477.2 crore from Rs 486.7 crore in the year ago period.

For the full year ended March 31, 2020 the PBT stood at Rs 568.7 crore, a 31 per cent decline over Rs 824.7 crore in the previous year. Total income for the year was down nine per cent at

Topics : Natco Pharma

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in